U.S. Mortgage REITs Stock News

NYSE:VYX
NYSE:VYXSoftware

Assessing NCR Voyix (VYX) Valuation After Prolonged Share Price Weakness

Why NCR Voyix (VYX) Is On Investors’ Radar Today NCR Voyix (VYX) is drawing fresh attention after a period of weak share performance, with the stock around $9.47 and total return figures over the past year and past 3 months reflecting double digit declines. With revenue of about $2.65b and a reported net loss of $62 million, investors are evaluating how this digital commerce business, focused on retailers and restaurants across multiple regions, is managing the balance between growth...
NYSE:TNC
NYSE:TNCMachinery

Tennant Sets 2026 Meeting Timeline As Undervalued Shares Show Steady Gains

Tennant Company set the date for its 2026 annual meeting of shareholders. The company also announced the deadline for shareholders to nominate director candidates for the 2026 board election. The update outlines the timetable that will guide board nominations and voting for NYSE:TNC. Tennant, trading on the NYSE under ticker NYSE:TNC, recently closed at $80.84. The stock is up 5.5% over the past week, 5.0% over the past month, and 9.3% year to date, while showing a 4.1% decline over the...
NYSE:PHIN
NYSE:PHINAuto Components

Assessing PHINIA (PHIN) Valuation After Recent Share Price Momentum And Conflicting Fair Value Signals

PHINIA: recent returns and earnings context PHINIA (PHIN) has attracted attention after a recent period of positive share price performance, with the stock showing gains over the past week, month and past 3 months alongside reported revenue and net income figures. See our latest analysis for PHINIA. At a latest share price of US$71.08, PHINIA has seen a firm build up in momentum, with a 33.16% 3 month share price return and a 44.23% 1 year total shareholder return. These figures point to...
NasdaqCM:ONDS
NasdaqCM:ONDSCommunications

Ondas (ONDS) Faces Short-Seller Scrutiny: Sustainable Strategy or Fragile Acquisition-Driven Growth Story?

In early February 2026, JCapital Research released a critical report on Ondas Holdings, questioning its acquisition-driven business model, reliance on share issuance for funding, and aspects of management governance and financial sustainability. This scrutiny landed just as Ondas was expanding its defense-focused autonomous systems footprint through the planned acquisition of UK-based Rotron Aero and new government drone contracts. We’ll now explore how JCapital’s critique of Ondas’...
NYSE:CI
NYSE:CIHealthcare

FTC Deal Reshapes Cigna’s Express Scripts Margins And PBM Positioning

Federal Trade Commission reaches a settlement with Cigna Group’s Express Scripts unit, requiring major reforms to its pharmacy benefit management practices. Key changes include ending spread pricing, adopting cost plus reimbursement for independent pharmacies, increasing transparency on drug spending, and relocating its group purchasing organization to the U.S. The settlement carries implications for drug pricing, patient costs, and how pharmacy benefit managers operate across the U.S...
NYSE:COUR
NYSE:COURConsumer Services

Coursera Udemy Merger Targets Cost Synergies And AI Focused Growth

Coursera (NYSE:COUR) has entered into a merger agreement with Udemy, combining two major online learning platforms. The companies outlined expected annual cost synergies and product fit across their course catalogs and learner bases. Management also highlighted plans to use AI native products and data driven tools across the combined platform. Coursera is coming into this merger with a share price of $5.98 and a mixed recent track record, including a 22.3% decline over the past year and a...
NYSE:RVTY
NYSE:RVTYLife Sciences

Assessing Revvity (RVTY) Valuation After New SLAS2026 Lab Automation Launches

What the SLAS2026 product launches mean for Revvity stock Revvity (RVTY) just used the SLAS2026 conference to roll out several new tools for high throughput drug discovery, including a high content screening system, a multimode plate reader, and an automated liquid handling workstation. For you as an investor, the focus is not the trade show itself, but what these launches say about how Revvity is trying to compete in automated, data heavy lab workflows that many pharma and biotech customers...
NasdaqGS:BNTX
NasdaqGS:BNTXBiotechs

BioNTech Hire Signals People Focus As Oncology Plans And Valuation Attract Attention

BioNTech (NasdaqGS:BNTX) has created a new Chief People Officer role. Kylie Jimenez has been appointed to the position, effective immediately. The move is tied to BioNTech’s goal of becoming a multi product oncology leader beyond its COVID 19 work. BioNTech, known widely for its COVID 19 vaccine partnership, is working to build a broader pipeline in oncology and other therapeutic areas. The new Chief People Officer role indicates that leadership views talent, organizational design, and...
NasdaqGS:ON
NasdaqGS:ONSemiconductor

Is ON Semiconductor (ON) Pricing In Recent End Market Headlines Too Generously?

If you are wondering whether ON Semiconductor's current share price reflects its true worth, this article will help you unpack what the numbers are saying about value. The stock last closed at US$63.10, with returns of 5.4% over 7 days, 2.0% over 30 days, 11.3% year to date, 23.1% over 1 year, a 24.7% decline over 3 years, and 52.9% over 5 years. Recent news coverage has focused on ON Semiconductor's role in key semiconductor end markets and how investors are weighing that against sector...
NYSE:OKLO
NYSE:OKLOElectric Utilities

Why Oklo (OKLO) Is Down 27.8% After Uranium Sector Weakness Clouds Its Fuel-Cost Assumptions And What's Next

In recent days, Oklo has come under pressure as analyst reports and sector-wide weakness in uranium and nuclear-energy names raised questions about how higher nuclear fuel costs and easing geopolitical risk premiums could affect its advanced reactor business model. At the same time, the company still benefits from substantial U.S. government support and large-scale tech partnerships, creating an unusual mix of perceived opportunity and execution risk for a pre-revenue nuclear...
NYSE:PRLB
NYSE:PRLBMachinery

Proto Labs (PRLB) Valuation Check After Recent Share Price Swings And Mixed Return Profile

Proto Labs (PRLB) is back on investor radars after recent share price swings, prompting a closer look at how its digital manufacturing business, profitability, and recent returns fit into a broader portfolio. See our latest analysis for Proto Labs. Recent moves have been mixed, with a 1 day share price return of a 1.83% decline and a 90 day share price return of 7.12%, while the 1 year total shareholder return of 18.22% hints at improving momentum despite a weaker 5 year total shareholder...
NYSE:MTD
NYSE:MTDLife Sciences

Should Mettler-Toledo’s Strong 2025 Results and 2026 Sales Outlook Require Action From MTD Investors?

Mettler-Toledo International Inc. recently reported its full-year 2025 results, with sales of US$4,026.40 million and net income of US$869.19 million, alongside higher basic and diluted earnings per share from continuing operations versus the prior year. The company also issued 2026 guidance calling for local currency sales increases in both the first quarter and full year, giving investors a clearer view of expected near-term business trends. Next, we’ll examine how Mettler-Toledo’s outlook...
NYSE:RTX
NYSE:RTXAerospace & Defense

Did Long-Term U.S. Missile Contracts Just Shift RTX's (RTX) Defense Modernization Investment Narrative?

Recently, Raytheon, an RTX business, entered into a series of long-term framework agreements with the U.S. Department of Defense to significantly expand production of key munitions including Tomahawk, AMRAAM, SM-3 and SM-6 missiles, backed by investments in facilities, technology and workforce over periods of up to seven years. The scale and duration of these missile production agreements highlight how deeply embedded RTX has become in U.S. defense modernization and high-volume weapons...
NYSE:JNJ
NYSE:JNJPharmaceuticals

ERLEADA Real World Survival Data Adds Weight To Johnson And Johnson Story

Johnson & Johnson (NYSE:JNJ) released new real world evidence on ERLEADA for metastatic castration sensitive prostate cancer. The study reports a significant survival benefit and reduced risk of death compared with darolutamide. The analysis follows FDA aligned methodological standards and provides head to head, real world comparative data. For a company like Johnson & Johnson, whose pharmaceutical arm is a core part of its business, real world data like this can be as important as headline...
NasdaqGS:NTRA
NasdaqGS:NTRABiotechs

Is Natera (NTRA) Quietly Redefining Its Moat With Multi-Front Cell-Free DNA Expansion?

Natera has recently advanced three major programs: launching the EDEN study for a new non-invasive prenatal preeclampsia risk test, submitting an FDA premarket approval application for its Signatera CDx assay in muscle-invasive bladder cancer, and completing enrollment in a key Prospera Heart trial aiming to reduce invasive biopsies in transplant care. Together, these moves highlight how Natera is trying to extend its cell-free DNA technology across prenatal health, oncology, and transplant...
NasdaqGS:CRDO
NasdaqGS:CRDOSemiconductor

Credo’s Blue Heron Retimer Targets Key AI Data Center Bottlenecks

Credo Technology Group Holding (NasdaqGS:CRDO) introduced its Blue Heron 224G AI scale up retimer for extended cable and backplane use in AI infrastructure. The product targets longer reach connections between GPUs and switch ICs while aiming to maintain high signal integrity. The launch focuses on AI data center deployments that require flexible rack and system layouts for hyperscale workloads. Credo Technology, through its networking and connectivity portfolio, is positioning this launch...
NYSE:UI
NYSE:UICommunications

Stronger Earnings And Dividend Hike Could Be A Game Changer For Ubiquiti (UI)

Ubiquiti Inc. has reported past second-quarter and six-month results to December 31, 2025, with sales and net income higher than the prior year, and declared a US$0.80 per share cash dividend payable on February 23, 2026 to shareholders of record on February 17, 2026. The combination of stronger earnings per share from continuing operations and the continued cash dividend underscores Ubiquiti’s focus on returning capital while growing its business scale. With these stronger earnings figures...
NasdaqGS:IRDM
NasdaqGS:IRDMTelecom

Iridium Communications (IRDM) Valuation Check After Recent Share Price Swings

Iridium Communications: Recent Returns and Business Profile Iridium Communications (IRDM) has been drawing attention after a mixed stretch in its share price, with a 1 day return showing a 1.9% decline, contrasted with positive moves over the month and the past 3 months. The company runs a global mobile satellite communications business from its headquarters in McLean, Virginia, serving commercial customers, governments, non governmental organizations, and consumers with voice, data,...
NYSE:UDR
NYSE:UDRResidential REITs

What UDR (UDR)'s Upbeat Analyst Sentiment Ahead of Earnings Means For Shareholders

UDR Inc., an apartment-focused REIT, recently drew attention as Wall Street analysts issued positive expectations for its upcoming quarterly results, including modest year-over-year increases in earnings per share and revenues. The company’s Zacks Rank #2 (Buy) and anticipated outperformance versus the broader market highlight how analyst sentiment and interest-rate expectations are shaping perceptions of UDR’s income-focused appeal. We’ll now examine how this upbeat analyst outlook ahead of...
NYSEAM:UEC
NYSEAM:UECOil and Gas

Assessing Uranium Energy (UEC) Valuation As Project Vault Spurs Institutional Buying

A surge in institutional buying of Uranium Energy (UEC) shares has coincided with the US government’s new Project Vault initiative, which focuses on securing domestic critical minerals and is drawing fresh attention to American uranium producers. See our latest analysis for Uranium Energy. Despite a 6.58% one day share price decline to US$15.04 and a 19.14% pullback over the past week, Uranium Energy still has a 23.28% 90 day share price return and a very large 5 year total shareholder...
NYSE:SHAK
NYSE:SHAKHospitality

Is Shake Shack (SHAK) Pricing Reflect Its Mixed Share Price Performance And Rich Valuation Metrics

If you have ever wondered whether Shake Shack's current share price reflects what you are actually getting as an investor, you are not alone. The stock recently closed at US$93.07, with returns of 5.7% over 7 days, 3.6% over 30 days, 11.5% year to date, 64.1% over 3 years, and a 19.2% decline over 1 year. Taken together, this gives a mixed picture of how the market has been reassessing it over different timeframes. Recent coverage has focused on Shake Shack as a branded fast casual player...
NasdaqGS:POOL
NasdaqGS:POOLRetail Distributors

Is Pool Corp (POOL) Now Pricing In Too Much After Recent Share Price Rebound?

Wondering if Pool at around US$257 per share still lines up with its underlying business, or if the stock is now out of sync with its fundamentals. The share price has seen mixed returns, with a 0.8% move over the last 7 days, 7.6% over the last 30 days and 12.1% year to date. Over longer periods, the 1 year return sits at a 22.6% decline and the 3 and 5 year returns are 28.8% and 17.2% declines respectively. Recent coverage has focused on how Pool fits into broader consumer and housing...
NYSE:GLOB
NYSE:GLOBIT

Assessing Globant (GLOB) Valuation After Q3 2025 Beat And Enterprise AI 2.3 Launch

Q3 results and AI platform upgrade put Globant (GLOB) in focus Globant (GLOB) is back on investors’ radar after Q3 2025 revenues came in slightly above the top end of guidance, alongside strong free cash flow and an October upgrade to its Enterprise AI platform. See our latest analysis for Globant. Despite the Q3 beat and the Enterprise AI 2.3 upgrade, Globant’s recent share price momentum has been weak, with a 30 day share price return of a 17.64% decline and a 1 year total shareholder...